We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE icon
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.89B
$28.2M 6.43%
1,057,238
– –
ABVX
2
Abivax
ABVX
$9.95B
$15.1M 3.43%
113,031
-223
-0.2% -$25.2K
RVMD icon
3
Revolution Medicines
RVMD
$45.2B
$12.5M 2.86%
66,983
-2,326
-3% -$340K
DFTX
4
Definium Therapeutics
DFTX
$5.11B
$11.4M 2.6%
242,884
+57,028
+31% +$1.41M
IMVT icon
5
Immunovant
IMVT
$8.08B
$10.7M 2.44%
277,873
+52,734
+23% +$1.61M
PRAX icon
6
Praxis Precision Medicines
PRAX
$9.92B
$10.1M 2.31%
30,210
+3,887
+15% +$1.23M
RLAY icon
7
Relay Therapeutics
RLAY
$4.17B
$9.47M 2.16%
506,235
+84,354
+20% +$1.22M
ALKS icon
8
Alkermes
ALKS
$7.86B
$9.39M 2.14%
179,256
+106,067
+145% +$4.14M
PCVX icon
9
Vaxcyte
PCVX
$9.1B
$8.7M 1.98%
149,739
+25,092
+20% +$1.36M
TNGX icon
10
Tango Therapeutics
TNGX
$3.84B
$8.13M 1.85%
260,070
+155,877
+150% +$3.85M
LQDA icon
11
Liquidia Corp
LQDA
$6.14B
$7.81M 1.78%
97,896
-1,848
-2% -$99K
COGT icon
12
Cogent Biosciences
COGT
$6.06B
$7.31M 1.67%
188,780
-8,271
-4% -$289K
GPCR icon
13
Structure Therapeutics
GPCR
$3.38B
$7.02M 1.6%
130,784
+6,875
+6% +$304K
ELVN icon
14
Enliven Therapeutics
ELVN
$4.37B
$7M 1.6%
137,866
+64,764
+89% +$2.75M
AMLX icon
15
Amylyx Pharmaceuticals
AMLX
$3.78B
$6.93M 1.58%
386,080
+33,995
+10% +$526K
SYRE icon
16
Spyre Therapeutics
SYRE
$7.69B
$6.91M 1.57%
77,807
-68,457
-47% -$5M
LBRX
17
LB Pharmaceuticals
LBRX
$1.53B
$6.86M 1.57%
211,511
+37,916
+22% +$1.11M
CYTK icon
18
Cytokinetics
CYTK
$10.3B
$6.65M 1.52%
78,003
+19,360
+33% +$1.39M
CCCC icon
19
C4 Therapeutics
CCCC
$460M
$6.3M 1.44%
+1,348,136
New +$4.61M
TYRA icon
20
Tyra Biosciences
TYRA
$1.48B
$5.9M 1.35%
184,774
+53,470
+41% +$1.77M
ALMS
21
Alumis Inc
ALMS
$1.47B
$5.63M 1.28%
199,968
+87,039
+77% +$2.03M
PHVS icon
22
Pharvaris
PHVS
$2.5B
$5.55M 1.27%
160,494
+62,628
+64% +$1.89M
TARS icon
23
Tarsus Pharmaceuticals
TARS
$3.65B
$5.48M 1.25%
87,060
+34,596
+66% +$2.21M
CMPS
24
Compass Pathways
CMPS
$1.84B
$5.25M 1.2%
371,120
+6,760
+2% +$68.6K
DNTH icon
25
Dianthus Therapeutics
DNTH
$6.03B
$4.98M 1.14%
51,125
+15,538
+44% +$1.36M
1
2 3 4 5

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.